- FDA puts Geron's (GERN) IND application for imetelstat on full clinical hold. This stops the Phase 2 trial for essential thrombocythemia and the Phase 2 for multiple myeloma. It will probably delay the start of the Phase 2 for myelofibrosis.
- Imetelstat may be toxic to the liver based on abnormal function tests.
- Geron must determine if the effects are reversible upon cessation on the drug.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Mon, 1:00PM)
at CNBC.com (Nov 14, 2014)
at CNBC.com (Nov 3, 2014)
at CNBC.com (Aug 13, 2014)
at CNBC.com (Jun 12, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs